4 studies found for:    TBR-652
Show Display Options
Rank Status Study
1 Completed A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
Condition: HIV-1 Infection
Interventions: Drug: TBR-652;   Drug: TBR-652 Matching Placebo;   Drug: TBR-652 50 mg;   Drug: TBR-652 75 mg;   Drug: TBR-652 100 mg;   Drug: TBR-652 150 mg
2 Completed Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
Condition: HIV-infection/AIDS
Interventions: Drug: Cenicriviroc;   Drug: Dolutegravir;   Drug: Midazolam
3 Completed Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus
Condition: HIV-1 Infection
Interventions: Drug: Cenicriviroc 100 mg;   Drug: Cenicriviroc 200 mg + Truvada;   Drug: Sustiva + Truvada
4 Terminated Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Condition: HIV Infection
Intervention:

Indicates status has not been verified in more than two years